Scaled Production, Dose-Sparing Immunogenicity, and Biodistribution of Short Carbon Nanotubes as mRNA Vaccine Delivery Vehicles
- 1Luna Labs USA , 706 Forest St., Suite A , , ,
- 2University of Virginia , , , ,
- 3Columbia University Irving Medical Center , , , ,
Abstract
Clinical translation of carbon nanotube (CNT)-based biomedical technologies requires a comprehensive understanding of scalable manufacturing, in vivo behavior, and dose efficiency. Here, we investigate NanoVac, a vaccine delivery platform based on functionalized short carbon nanotubes (SCNTs). We achieved scalable production and purification of NanoVac using tangential flow filtration (TFF), providing a reproducible process compatible with future Good Manufacturing Practice (GMP) development. To characterize its in vivo properties, we radiolabeled NanoVac with 89Zr via deferoxamine (DFO) chelation and evaluated it using longitudinal positron emission tomography (PET) imaging. After intramuscular administration in mice, NanoVac showed prolonged retention at the injection site, limited systemic distribution, and minimal accumulation in major organs, including the liver and spleen. NanoVac-associated radioactivity was gradually eliminated through renal and biliary excretion pathways over a 7-day observation period. Compared with other nonlipid nanocarriers, including polymeric nanoparticles and inorganic systems that often face challenges related to biodegradability, toxicity, or large-scale manufacturing, NanoVac combines scalable production with favorable biodistribution and retention characteristics. Immunogenicity studies demonstrated that NanoVac-mediated delivery of HIV-1 trimer-encoding mRNA achieved robust antibody responses at substantially reduced mRNA doses, with low-dose formulations (0.1–1 μg/animal) producing responses comparable to those observed with a 30 μg dose. In addition, NanoVac alone stimulated T-cell responses, supporting its potential role as both a delivery vehicle and an immune-modulating component. These findings establish the manufacturing feasibility, pharmacokinetic profile, and dose-sparing potential of NanoVac, thereby supporting its further development as a scalable vaccine delivery platform for rapid-response applications.
Related
- Ergothioneine as a nutraceutical antioxidant: sustainable production, food applications and delivery systems
- Development of an effective direct qPCR method for cell therapy product quantification in non-clinical biodistribution studies.
- The role of extracardiac radiotracer biodistribution in the evaluation of cardiac amyloidosis: a retrospective multicenter study on [99mTc]Tc-DPD and [99mTc]Tc-HMDP
- Asymmetrical Glyco-Engineering of Monoclonal Antibodies Provides Insights into α-Gal Immunogenicity
- The nucleolar deubiquitinase OTUD4 coordinates spatial organization of perinucleolar heterochromatin to restrain tumor immunogenicity
BibTeX
@article{xu2026scaled,
title = {{Scaled Production, Dose-Sparing Immunogenicity, and Biodistribution of Short Carbon Nanotubes as mRNA Vaccine Delivery Vehicles}},
author = {Yang Xu and Olivia Vest and Brad Brooks and Jackson McNeal and Maurits A. Jansen and Jiang He and Moriya Tsuji and Christopher Tison},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c06230},
url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c06230/5455908/Scaled-Production-Dose-Sparing-Immunogenicity-and},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Scaled Production, Dose-Sparing Immunogenicity, and Biodistribution of Short Carbon Nanotubes as mRNA Vaccine Delivery Vehicles
AU - Yang Xu
AU - Olivia Vest
AU - Brad Brooks
AU - Jackson McNeal
AU - Maurits A. Jansen
AU - Jiang He
AU - Moriya Tsuji
AU - Christopher Tison
PY - 2026
DA - 2026/10/22
JO - ACS Omega
DO - 10.1021/acsomega.6c06230
UR - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c06230/5455908/Scaled-Production-Dose-Sparing-Immunogenicity-and
AB - Clinical translation of carbon nanotube (CNT)-based biomedical technologies requires a comprehensive understanding of scalable manufacturing, in vivo behavior, and dose efficiency. Here, we investigate NanoVac, a vaccine delivery platform based on functionalized short carbon nanotubes (SCNTs). We achieved scalable production and purification of NanoVac using tangential flow filtration (TFF), providing a reproducible process compatible with future Good Manufacturing Practice (GMP) development. To characterize its in vivo properties, we radiolabeled NanoVac with 89Zr via deferoxamine (DFO) chelation and evaluated it using longitudinal positron emission tomography (PET) imaging. After intramuscular administration in mice, NanoVac showed prolonged retention at the injection site, limited systemic distribution, and minimal accumulation in major organs, including the liver and spleen. NanoVac-associated radioactivity was gradually eliminated through renal and biliary excretion pathways over a 7-day observation period. Compared with other nonlipid nanocarriers, including polymeric nanoparticles and inorganic systems that often face challenges related to biodegradability, toxicity, or large-scale manufacturing, NanoVac combines scalable production with favorable biodistribution and retention characteristics. Immunogenicity studies demonstrated that NanoVac-mediated delivery of HIV-1 trimer-encoding mRNA achieved robust antibody responses at substantially reduced mRNA doses, with low-dose formulations (0.1–1 μg/animal) producing responses comparable to those observed with a 30 μg dose. In addition, NanoVac alone stimulated T-cell responses, supporting its potential role as both a delivery vehicle and an immune-modulating component. These findings establish the manufacturing feasibility, pharmacokinetic profile, and dose-sparing potential of NanoVac, thereby supporting its further development as a scalable vaccine delivery platform for rapid-response applications.
SN - 2470-1343
ER -